ArticleTranslational cancer research2024
Construction of a disulfidptosis-related lncRNAs signature of the subtype, prognostic, and immunotherapy in neuroblastoma.
Article in Translational cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development of a prognostic model for overall survival in neuroblastoma based on Schwann cell-specific genes, clinical predictors, and MYCN amplification.Translational cancer research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Disulfidptosis is an emerging form of regulated cell death distinguished by abnormal disulfide stress and the collapse of the actin network. This study was to construct a prognostic model based on disulfidptosis-related lncRNAs (DRLs) to enhance survival prediction and assess their viability as biomarkers for immunotherapy response in neuroblastoma (NB). Methods: Transcriptomic and clinical data from NB patients were obtained from the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) and Gene Expression Omnibus (GEO) databases. DRLs linked to overall survival (OS) were identified using Pearson correlation and univariate Cox regression analyses. Molecular subtypes of NB were determined through consensus clustering. Immune cell infiltration was assessed with multiple algorithms. A prognostic model was constructed using least absolute shrinkage and selection operator (LASSO) regression. Tumor mutational burden (TMB) analysis on somatic mutations from the TARGET database explored the TMB and risk score relationship. Patient responses to immunotherapy and anti-tumor drugs were predicted using tumor immune dysfunction and exclusion (TIDE), Tumor Inflammation Signature (TIS), Genomics of Drug Sensitivity in Cancer (GDSC) database, and CellMiner tools. Results: We identified 151 DRLs associated with OS and defined three distinct DRLs subtypes. Using eight of these, we created a prognostic model. This model was proven independently significant and divided NB patients into high and low-risk groups. The high-risk group showed poorer OS, reduced immune cell presence and infiltration, and weaker response to immunotherapy. Conversely, the low-risk group demonstrated potential immunotherapy effectiveness and increased sensitivity to anti-tumor drugs. Conclusions: We established a prognostic model based on DRLs to predict the prognosis of NB patients, assess the immune cell infiltration, analyze TMB, evaluate the effectiveness of immunotherapy, and gauge sensitivity to anti-tumor drug treatments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.